<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROMETHAZINE VC- promethazine hydrochloride and phenylephrine hydrochloride syrup </strong><br>Preferred Pharmaceuticals, Inc.<br></p></div>
<h1>
<span class="Bold">PROMETHAZINE VC SYRUP</span><br><span class="Bold"> (PROMETHAZINE HYDROCHLORIDE, USP AND PHENYLEPHRINE HYDROCHLORIDE, USP)</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c6e5091f-fb95-4ccb-bc0c-ebc790ed60f9"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_75d0ecbb-9110-4f1d-8b60-357b41b03597"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each 5 mL (one teaspoonful), for oral administration contains: Promethazine hydrochloride 6.25 mg; phenylephrine hydrochloride 5 mg. Alcohol 7%.</p>
<p>Inactive Ingredients: Apricot peach flavor, ascorbic acid, citric acid, FD&amp;C yellow #6, menthol, methylparaben, propylene glycol, propylparaben, purified water, saccharin sodium, sodium benzoate, sodium citrate and sucrose.</p>
<p>Promethazine hydrochloride, a phenothiazine derivative, is chemically designated as (±)-10-[2-(Dimethylamino)propyl] phenothiazine monohydrochloride.</p>
<p>Promethazine hydrochloride occurs as a white to <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> yellow, practically odorless, crystalline powder which slowly oxidizes and turns blue on prolonged exposure to air. It is soluble in water and freely soluble in alcohol. It has a molecular weight of 320.88, a molecular formula of C<span class="Sub">17</span>H<span class="Sub">20</span>N<span class="Sub">2</span>S•HCI, and the following structural formula:</p>
<div class="Figure">
<a name="id279"></a><img alt="Z:\i4i\SPL Submissions\Prometh VC Plain Qualitest\PROMETHAZINEVC01152015\1ed2a01c-6521-451e-819f-7464562314a3-01.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1ed2a01c-6521-451e-819f-7464562314a3&amp;name=1ed2a01c-6521-451e-819f-7464562314a3-01.jpg">
</div>
<p>Phenylephrine hydrochloride is a sympathomimetic amine salt which is chemically designated as (-)-m-Hydroxy-α-[(methylamino)methyl] benzyl alcohol hydrochloride. It occurs as white or nearly white crystals, having a bitter taste. It is freely soluble in water and alcohol. Phenylephrine hydrochloride is subject to oxidation and must be protected from light and air. It has a molecular weight of 203.67, a molecular formula of C<span class="Sub">9</span>H<span class="Sub">13</span>NO<span class="Sub">2</span>•HCI, and the following structural formula:</p>
<div class="Figure">
<a name="id284"></a><img alt="Z:\i4i\SPL Submissions\Prometh VC Plain Qualitest\PROMETHAZINEVC01152015\1ed2a01c-6521-451e-819f-7464562314a3-02.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1ed2a01c-6521-451e-819f-7464562314a3&amp;name=1ed2a01c-6521-451e-819f-7464562314a3-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_68d41f82-bffe-43f4-a046-b675a8ada98f"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_0f065123-28ec-4f02-a9bb-19ae18c8a326"></a><a name="section-3.1"></a><p></p>
<h2>Promethazine:</h2>
<p class="First">Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of chlorpromazine) of dopamine antagonist properties.</p>
<p>Promethazine is an H<span class="Sub">1</span> receptor blocking agent. In addition to its antihistaminic action, it provides clinically useful sedative and antiemetic effects.</p>
<p>Promethazine is well absorbed from the gastrointestinal tract. Clinical effects are apparent within 20 minutes after oral administration and generally last four to six hours, although they may persist as long as 12 hours. Promethazine is metabolized by the liver to a variety of compounds; the sulfoxides of promethazine and N-demethylpromethazine are the predominant metabolites appearing in the urine.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_7de2aa71-49b5-47e4-9f2d-5229c88edc09"></a><a name="section-3.2"></a><p></p>
<h2>Phenylephrine:</h2>
<p class="First">Phenylephrine is a potent postsynaptic α-receptor agonist with little effect on β-receptors of the heart. Phenylephrine has no effect on β-adrenergic receptors of the bronchi or peripheral blood vessels. A direct action at receptors accounts for the greater part of its effects, only a small part being due to its ability to release norepinephrine.</p>
<p>Therapeutic doses of phenylephrine mainly cause <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>. Phenylephrine increases resistance and, to a lesser extent, decreases capacitance of blood vessels. Total peripheral resistance is increased, resulting in increased systolic and diastolic blood pressure. Pulmonary arterial pressure is usually increased, and renal blood flow is usually decreased. Local <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> and hemostasis occur following topical application or infiltration of phenylephrine into tissues. The main effect of phenylephrine on the heart is <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; it produces a positive inotropic effect on the myocardium in doses greater than those usually used therapeutically. Rarely, the drug may increase the <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> of the heart, causing <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">Cardiac output</span> is decreased slightly. Phenylephrine increases the work of the heart by increasing peripheral arterial resistance.</p>
<p>Phenylephrine has a mild central stimulant effect.</p>
<p>Following oral administration or topical application of phenylephrine to the mucosa, constriction of blood vessels in the nasal mucosa relieves <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">head colds</span>. Following oral administration, nasal decongestion may occur within 15 or 20 minutes and may persist for up to 4 hours.</p>
<p>Phenylephrine is irregularly absorbed from and readily metabolized in the gastrointestinal tract. Phenylephrine is metabolized in the liver and intestine by monoamine oxidase. The metabolites and their route and rate of excretion have not been identified. The pharmacologic action of phenylephrine is terminated at least partially by uptake of the drug into tissues.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_a77c6359-3f60-4ce0-ad48-e444f61a812d"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Promethazine hydrochloride and phenylephrine hydrochloride syrup is indicated for the temporary relief of upper respiratory symptoms, including <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_a70c4c7d-126e-49b9-86d6-1cd1aae622ab"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Promethazine is contraindicated in <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines.</p>
<p>Antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>Phenylephrine is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or with peripheral <span class="product-label-link" type="condition" conceptid="4311420" conceptname="Vascular insufficiency">vascular insufficiency</span> (<span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> may result with risk of <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> or <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> of compromised vascular beds). Phenylephrine should not be used in patients known to be hypersensitive to the drug or in those receiving a monoamine oxidase inhibitor (MAOI).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_7be85ef8-ed76-46d4-989e-ef01731832f6"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Warning">
<a name="LINK_8fbf2b85-6a32-4cca-9a54-60c0cf9febd2"></a><a name="section-6.1"></a><p></p>
<h2></h2>
<p class="First">WARNING:</p>
<p>PROMETHAZINE HYDROCHLORIDE SHOULD NOT BE USED IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE BECAUSE OF THE POTENTIAL FOR FATAL <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>.</p>
<p>POSTMARKETING CASES OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, INCLUDING FATALITIES, HAVE BEEN REPORTED WITH USE OF PROMETHAZINE HYDROCHLORIDE IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE. A WIDE RANGE OF WEIGHT-BASED DOSES OF PROMETHAZINE HYDROCHLORIDE HAVE RESULTED IN <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> IN THESE PATIENTS.</p>
<p>CAUTION SHOULD BE EXERCISED WHEN ADMINISTERING PROMETHAZINE HYDROCHLORIDE TO PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER. IT IS RECOMMENDED THAT THE LOWEST EFFECTIVE DOSE OF PROMETHAZINE HYDROCHLORIDE BE USED IN PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER AND CONCOMITANT ADMINISTRATION OF OTHER DRUGS WITH RESPIRATORY DEPRESSANT EFFECTS BE AVOIDED.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_94c36059-1f23-46e9-afb2-917227a95219"></a><a name="section-6.1"></a><p></p>
<h2>Promethazine:</h2>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_bf5fd2ff-16d2-4565-904b-b4863a720328"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span> –</span></h3>
<p class="First">Promethazine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating machinery. The impairment may be amplified by concomitant use of other central nervous system depressants such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should either be eliminated or given in reduced dosage in the presence of promethazine HCl  	(see <span class="Bold"><a href="#LINK_a6c4495a-7177-47e7-ad5d-03d657141152">	PRECAUTIONS - Information For Patients</a></span>	 and <span class="Bold"><a href="#LINK_86b3da7c-d6b8-44f2-866b-6194381699cd">	Drug Interactions</a></span>	).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_771f2fe2-dede-4d90-8bc6-3c1ff2522492"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> –</span></h3>
<p class="First">Promethazine may lead to potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p>Use of promethazine in patients with compromised respiratory function (e.g., <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>) should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_a686faf9-023b-44f8-801d-c081fc7e5a7d"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Bold">Lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Threshold –</span></h3>
<p class="First">Promethazine may lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. It should be used with caution in persons with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders or in persons who are using concomitant medications, such as narcotics or local anesthetics, which may also affect <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_bbec214e-073d-4845-aa65-6075bb9652c3"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Bone Marrow Depression</span> –</span></h3>
<p class="First">Promethazine should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported, usually when promethazine HCl has been used in association with other known marrow toxic agents.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_805045b9-268b-480f-ad21-82670212fb75"></a><a name="section-6.1.5"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> –</span></h3>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with promethazine HCl alone or in combination with antipsychotic drugs. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>).</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary central nervous system (CNS) pathology.</p>
<p>The management of NMS should include 1) immediate discontinuation of promethazine HCl, antipsychotic drugs, if any, and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.</p>
<p>Since recurrences of NMS have been reported with phenothiazines, the reintroduction of promethazine HCl should be carefully considered.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_762a2330-0c55-425b-a53f-f678378f89a6"></a><a name="section-7"></a><p></p>
<h1>Use In Pediatric Patients</h1>
<p class="First"><span class="Bold">PROMETHAZINE PRODUCTS ARE CONTRAINDICATED FOR USE IN PEDIATRIC PATIENTS LESS THAN TWO YEARS OF AGE.</span></p>
<p><span class="Bold">CAUTION SHOULD BE EXERCISED WHEN ADMINISTERING PROMETHAZINE PRODUCTS TO PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER BECAUSE OF THE POTENTIAL FOR FATAL <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span> AND <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">APNEA</span>, SOMETIMES ASSOCIATED WITH <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>, ARE STRONGLY ASSOCIATED WITH PROMETHAZINE PRODUCTS AND ARE NOT DIRECTLY RELATED TO INDIVIDUALIZED WEIGHT-BASED DOSING, WHICH MIGHT OTHERWISE PERMIT SAFE ADMINISTRATION. CONCOMITANT ADMINISTRATION OF PROMETHAZINE PRODUCTS WITH OTHER RESPIRATORY DEPRESSANTS HAS AN ASSOCIATION WITH <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, AND SOMETIMES <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>, IN PEDIATRIC PATIENTS.</span></p>
<p><span class="Bold">ANTIEMETICS ARE NOT RECOMMENDED FOR TREATMENT OF UNCOMPLICATED <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> IN PEDIATRIC PATIENTS, AND THEIR USE SHOULD BE LIMITED TO PROLONGED <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OF KNOWN ETIOLOGY. THE <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">EXTRAPYRAMIDAL SYMPTOMS</span> WHICH CAN OCCUR SECONDARY TO PROMETHAZINE HYDROCHLORIDE ADMINISTRATION MAY BE <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">CONFUSED</span> WITH THE CNS SIGNS OF UNDIAGNOSED PRIMARY DISEASE, e.g., <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">ENCEPHALOPATHY</span> OR REYE'S SYNDROME. THE USE OF PROMETHAZINE PRODUCTS SHOULD BE AVOIDED IN PEDIATRIC PATIENTS WHOSE SIGNS AND SYMPTOMS MAY SUGGEST REYE'S SYNDROME OR OTHER <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">HEPATIC DISEASES</span>.</span></p>
<p>Excessively large dosages of antihistamines, including promethazine hydrochloride, in pediatric patients may cause <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> (see <span class="Bold"><a href="#LINK_c5ce3fd4-ec3c-43f2-a13b-32abf084cae6">OVERDOSAGE</a></span>). <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have occurred with therapeutic doses and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of promethazine hydrochloride in pediatric patients. In pediatric patients who are acutely ill associated with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, there is an increased susceptibility to <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonias</span> with the use of promethazine HCl.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_08ac53c6-2afd-4207-8249-cb0addb0fa6c"></a><a name="section-8"></a><p></p>
<h1>Other Considerations</h1>
<p class="First">Administration of promethazine has been associated with reported <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_dc56192e-b5fd-4d50-b32b-1b9ae3de27bb"></a><a name="section-9"></a><p></p>
<h1>Phenylephrine:</h1>
<p class="First">Because phenylephrine is an adrenergic agent, it should be given with caution to patients with thyroid diseases, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and heart disease or those receiving tricyclic antidepressants.</p>
<p>Men with symptomatic, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hypertrophy</span> can experience <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> when given oral nasal decongestants.</p>
<p>Phenylephrine can cause a decrease in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, and extreme caution should be used when administering the drug parenterally or orally to patients with <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span>, to elderly individuals, and/or to patients with initially poor cerebral or coronary circulation.</p>
<p>Phenylephrine should be used with caution in patients taking diet preparations, such as amphetamines or phenylpropanolamine, because synergistic adrenergic effects could result in serious hypertensive response and possible <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_832b86cf-0050-4c77-a9be-5162c7256c40"></a><a name="section-10"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Animal reproduction studies have not been conducted with the drug combination—promethazine and phenylephrine. It is not known whether this drug combination can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Promethazine and phenylephrine should be given to a pregnant woman only if clearly needed.</p>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_a4ec4d24-34c7-4705-827a-69fcf6c597ca"></a><a name="section-10.1"></a><p></p>
<h2>General:</h2>
<p class="First">Drugs having anticholinergic properties should be used with caution in patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, stenosing <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, pyloroduodenal obstruction, and bladder-neck obstruction.</p>
<p>Promethazine should be used cautiously in persons with cardiovascular disease or impairment of liver function.</p>
<p>Phenylephrine should be used with caution in patients with cardiovascular disease, particularly <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_a6c4495a-7177-47e7-ad5d-03d657141152"></a><a name="section-10.2"></a><p></p>
<h2>Information For Patients:</h2>
<p class="First">Promethazine and phenylephrine may cause marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating machinery.  Ambulatory patients should be told to avoid engaging in such activities until it is known that they do not become drowsy or dizzy from promethazine and phenylephrine therapy. Children should be supervised to avoid potential harm in bike riding or in other hazardous activities.</p>
<p>The concomitant use of alcohol or other central nervous system depressants, including narcotic analgesics, sedatives, hypnotics, and tranquilizers, may have an additive effect and should be avoided or their dosage reduced.</p>
<p>Patients should be advised to report any <span class="product-label-link" type="condition" conceptid="4319906" conceptname="Dyskinesia">involuntary muscle movements</span>.</p>
<p>Avoid prolonged exposure to the sun.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_86b3da7c-d6b8-44f2-866b-6194381699cd"></a><a name="section-10.3"></a><p></p>
<h2>Drug Interactions:</h2>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_deedd9c0-e2fe-4674-b4f1-11fe9dd7cc37"></a><a name="section-10.3.1"></a><p></p>
<h3><span class="Bold">Promethazine</span></h3>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_09d80140-add0-4c9e-bf2a-0392d370f05f"></a><a name="section-10.3.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">CNS Depressants – </span></span></h3>
<p class="First">Promethazine may increase, prolong, or intensify the sedative action of other central nervous system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. When given concomitantly with promethazine, the dose of barbiturates should be reduced by at least one-half, and the dose of narcotics should be reduced by one-quarter to one-half. Dosage must be individualized. Excessive amounts of promethazine HCl relative to a narcotic may lead to <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> in the patient with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; these symptoms usually disappear with adequate control of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_6e9ffd62-7396-4557-94af-c262fdb44fa0"></a><a name="section-10.3.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Epinephrine – </span></span></h3>
<p class="First">Because of the potential for promethazine to reverse epinephrine's vasopressor effect, epinephrine should NOT be used to treat <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with promethazine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_cd4aad50-c1bd-4db0-981c-7d5f38aa1b15"></a><a name="section-10.3.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Anticholinergics – </span></span></h3>
<p class="First">Concomitant use of other agents with anticholinergic properties should be undertaken with caution.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_152387b1-6d6c-4fb4-bfc2-9badbb13845e"></a><a name="section-10.3.5"></a><p></p>
<h3><span class="Bold"><span class="Italics">Monoamine Oxidase Inhibitors (MAOI) – </span></span></h3>
<p class="First">Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_fdba23ba-86e8-4f7e-a703-6c7001aaf2c8"></a><a name="section-10.3.6"></a><p></p>
<h3><span class="Bold">Phenylephrine</span></h3>
<p class="First"><span class="Italics">Drug</span><br>Phenylephrine with prior administration of monoamine oxidase inhibitors (MAOI). <br>               Effect<br>               Cardiac pressor response potentiated. <br>               May cause acute <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>.</p>
<p><span class="Italics">Drug</span><br>Phenylephrine with tricyclic antidepressants. <br>               Effect<br>               Pressor response increased.</p>
<p><span class="Italics">Drug</span><br>Phenylephrine with ergot alkaloids. <br>               Effect<br>               Excessive <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>.</p>
<p><span class="Italics">Drug</span><br>Phenylephrine with bronchodilator sympathomimetic agents and with epinephrine or other sympathomimetics. <br>               Effect<br>               <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> or other <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may occur.</p>
<p><span class="Italics">Drug</span><br>Phenylephrine with atropine sulfate. <br>               Effect<br>               <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Reflex bradycardia</span> blocked; pressor response enhanced.</p>
<p><span class="Italics">Drug</span><br>Phenylephrine with prior administration of propranolol or other β-adrenergic blockers. <br>               Effect<br>               Cardiostimulating effects blocked.</p>
<p><span class="Italics">Drug</span><br>Phenylephrine with prior administration of phentolamine or other α-adrenergic blockers. <br>               Effect<br>               Pressor response decreased.</p>
<p><span class="Italics">Drug</span><br>Phenylephrine with diet preparations, such as amphetamines or phenylpropanolamine. <br>               Effect<br>               Synergistic adrenergic response.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_bf1a05b8-aa5c-4ca8-aae7-6b0ab599d185"></a><a name="section-10.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions:</h2>
<p class="First">The following laboratory tests may be affected in patients who are receiving therapy with promethazine hydrochloride.</p>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_67708458-fc1d-4006-94b9-25bef736f515"></a><a name="section-10.4.1"></a><p></p>
<h3><span class="Bold">Pregnancy Tests:</span></h3>
<p class="First">Diagnostic pregnancy tests based on immunological reactions between HCG and anti-HCG may result in false-negative or false-positive interpretations.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_6dc55239-760b-4211-8f2a-0d84f2b49c8a"></a><a name="section-10.4.2"></a><p></p>
<h3><span class="Bold">Glucose Tolerance Test:</span></h3>
<p class="First">An increase in blood glucose has been reported in patients receiving promethazine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_30c8ec5b-aa43-42b4-b232-aea7931d6c25"></a><a name="section-10.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment Of Fertility:</h2>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_50953118-90bf-44da-91bd-d22599cb31ca"></a><a name="section-10.5.1"></a><p></p>
<h3><span class="Bold">Promethazine:</span></h3>
<p class="First">Long-term animal studies have not been performed to assess the carcinogenic potential of promethazine, nor are there other animal or human data concerning carcinogenicity, mutagenicity, or impairment of fertility with this drug. Promethazine was nonmutagenic in the <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>  test system of Ames.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_8405aed6-0433-4361-9a83-8bf5a3886791"></a><a name="section-10.5.2"></a><p></p>
<h3><span class="Bold">Phenylephrine:</span></h3>
<p class="First">A study which followed the development of cancer in 143,574 patients over a four-year period indicated that in 11,981 patients who received phenylephrine (systemic or topical), there was no statistically significant association between the drug and cancer at any or all sites.</p>
<p>Long-term animal studies have not been performed to assess the carcinogenic potential of phenylephrine, nor are there other animal or human data concerning mutagenicity.</p>
<p>A study of the effects of adrenergic drugs on ovum transport in rabbits indicated that treatment with phenylephrine did not alter incidence of pregnancy; the number of implantations was significantly reduced when high doses of the drug were used.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_3b6c23e9-71cb-4a46-a294-449f1308b044"></a><a name="section-10.6"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_580fd4d8-95fa-4d46-a8e4-06f6105dccb3"></a><a name="section-10.6.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects –</span></h3>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_9ed981c0-28c9-47d1-89fe-eb42b7d243a1"></a><a name="section-10.6.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Category C.</span></h4>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_aeba61df-0889-4954-b635-7a1c04df4c79"></a><a name="section-10.6.1.2"></a><p></p>
<h4><span class="Bold">Promethazine:</span></h4>
<p class="First">Teratogenic effects have not been demonstrated in rat-feeding studies at doses of 6.25 and 12.5 mg/kg of promethazine HCl. These doses are from approximately 2.1 to 4.2 times the maximum recommended total daily dose of promethazine for a 50-kg subject, depending upon the indication for which the drug is prescribed. Daily doses of 25 mg/kg intraperitoneally have been found to produce fetal mortality in rats.</p>
<p>Specific studies to test the action of the drug on parturition, lactation, and development of the animal neonate were not done, but a general preliminary study in rats indicated no effect on these parameters. Although antihistamines have been found to produce fetal mortality in rodents, the pharmacological effects of histamine in the rodent do not parallel those in man. There are no adequate and well-controlled studies of promethazine in pregnant women.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_a04577d9-b83a-47ec-9358-2b570242a29b"></a><a name="section-10.6.1.3"></a><p></p>
<h4><span class="Bold">Phenylephrine:</span></h4>
<p class="First">A study in rabbits indicated that continued moderate overexposure to phenylephrine (3 mg/day) during the second half of pregnancy (22nd day of gestation to delivery) may contribute to perinatal wastage, <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span>, <span class="product-label-link" type="condition" conceptid="4273560" conceptname="Premature labor">premature labor</span>, and possibly fetal anomalies; when phenylephrine (3 mg/day) was given to rabbits during the first half of pregnancy (3rd day after mating for seven days), a significant number gave birth to litters of low birth weight. Another study showed that phenylephrine was associated with anomalies of aortic arch and with <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defect</span> in the chick embryo.</p>
<p>Promethazine and phenylephrine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_25ba8d13-fe7a-4dad-bcbe-f03590de30b2"></a><a name="section-10.6.2"></a><p></p>
<h3><span class="Bold">Nonteratogenic Effects -</span></h3>
<p class="First">Promethazine administered to a pregnant woman within two weeks of delivery may inhibit platelet aggregation in the newborn.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_9ee66130-0c8b-4c66-8dc0-b281a07aa5ee"></a><a name="section-10.7"></a><p></p>
<h2>Labor And Delivery:</h2>
<p class="First">Administration of phenylephrine to patients in late pregnancy or labor may cause fetal <span class="product-label-link" type="condition" conceptid="313601" conceptname="Oxygen supply absent">anoxia</span> or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> by increasing contractility of the uterus and decreasing uterine blood flow.</p>
<p>See also "<a href="#LINK_25ba8d13-fe7a-4dad-bcbe-f03590de30b2">Nonteratogenic Effects.</a>Nonteratogenic"</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_5e67f24a-3f8e-4af1-84c8-df9987ab10e2"></a><a name="section-10.8"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether promethazine or phenylephrine are excreted in human milk.</p>
<p>Caution should be exercised when promethazine and phenylephrine is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_8492b829-bba1-4359-bf04-cb5b864ea9f4"></a><a name="section-10.9"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First"><span class="Bold">PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE SYRUP IS CONTRAINDICATED FOR USE IN PEDIATRIC PATIENTS LESS THAN TWO YEARS OF AGE (</span>see <span class="Bold">WARNING:</span></p>
<p><span class="Bold">  </span>and <span class="Bold"><a href="#LINK_762a2330-0c55-425b-a53f-f678378f89a6">Use In Pediatric Patients</a></span>).</p>
<p>Promethazine hydrochloride and phenylephrine hydrochloride syrup should be used with caution in pediatric patients 2 years of age and older (see <span class="Bold"><a href="#LINK_762a2330-0c55-425b-a53f-f678378f89a6">WARNINGS –  Use In Pediatric Patients</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_fbb5062d-cc2e-44b7-8ee3-a95d34380cb4"></a><a name="section-10.10"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Clinical studies of promethazine hydrochloride and phenylephrine hydrochloride syrup did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Sedating drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over-sedation in the elderly; elderly patients generally should be started on low doses of promethazine hydrochloride and phenylephrine hydrochloride syrup and observed closely.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_4bafc41c-b4e7-4346-8142-88b991484720"></a><a name="section-11"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Promethazine:</span></p>
<p>Central Nervous System – <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> is the most prominent CNS effect of this drug. Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> such as <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, and tongue protrusion; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, excitation, <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonic</span>-like states, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> have also been reported.</p>
<p>Cardiovascular – Increased or decreased blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, faintness.</p>
<p>Dermatologic – <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Hematologic – <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>Gastrointestinal – <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p>Respiratory – <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (potentially fatal) and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (potentially fatal). (See <span class="Bold"><a href="#LINK_771f2fe2-dede-4d90-8bc6-3c1ff2522492">WARNINGS –  Promethazine; </a></span><a href="#LINK_771f2fe2-dede-4d90-8bc6-3c1ff2522492"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a>.)</p>
<p>Other – <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioneurotic edema</span>. <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</span> (potentially fatal) has also been reported. (See <span class="Bold"><a href="#LINK_805045b9-268b-480f-ad21-82670212fb75">WARNINGS –  Promethazine;</a></span><a href="#LINK_805045b9-268b-480f-ad21-82670212fb75"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></a>.)</p>
<p>Paradoxical Reactions – <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Hyperexcitability</span> and abnormal movements have been reported in patients following a single administration of promethazine HCI. Consideration should be given to the discontinuation of promethazine HCl and to the use of other drugs if these reactions occur. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> behavior have also been reported in some of these patients.</p>
<p><span class="Bold">Phenylephrine:</span></p>
<p>Nervous System – <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>Cardiovascular – <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (see "<span class="Bold"><a href="#LINK_7be85ef8-ed76-46d4-989e-ef01731832f6">WARNINGS</a></span>").</p>
<p>Other – <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Precordial pain</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_c5ce3fd4-ec3c-43f2-a13b-32abf084cae6"></a><a name="section-12"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_87b126cd-a4ac-43a5-b5a9-9adfabf44361"></a><a name="section-12.1"></a><p></p>
<h2>Promethazine:</h2>
<p class="First">Signs and symptoms of overdosage with promethazine HCl range from mild <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the central nervous system and cardiovascular system to profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. Other reported reactions include <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4259277" conceptname="Athetosis">athetosis</span>, and extensor-plantar reflexes (Babinski reflex).</p>
<p>Stimulation may be evident, especially in children and geriatric patients. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may rarely occur. A paradoxical reaction has been reported in children receiving single doses of 75 mg to 125 mg orally, characterized by <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span> and <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>.</p>
<p>Atropine-like signs and symptoms – <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4011326" conceptname="Fixed dilatation of pupil">fixed dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, as well as <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, may occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_df7520c0-3420-45ad-9787-7d3b4da38a29"></a><a name="section-12.2"></a><p></p>
<h2>Phenylephrine:</h2>
<p class="First">Signs and symptoms of overdosage with phenylephrine include <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Ventricular <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">premature beats</span> and short paroxysms of <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> may also occur. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> may be a symptom of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> may also be seen early in phenylephrine overdosage through stimulation of baroreceptors.</p>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_91969248-3837-45cf-937a-8f228052e521"></a><a name="section-12.2.1"></a><p></p>
<h3><span class="Bold">Treatment:</span></h3>
<p class="First">The treatment of overdosage with promethazine and phenylephrine is essentially symptomatic and supportive. Only in cases of extreme overdosage or individual sensitivity do vital signs including respiration, pulse, blood pressure, temperature, and EKG need to be monitored. Activated charcoal orally or by lavage may be given, or sodium or magnesium sulfate orally as a cathartic. Attention should be given to the re-establishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. Diazepam may be used to control <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span> and electrolyte losses should be corrected. Note that any depressant effects of promethazine are not reversed by naloxone. Avoid analeptics which may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> usually responds to the administration of norepinephrine or phenylephrine. EPINEPHRINE SHOULD NOT BE USED, since its use in a patient with partial adrenergic blockade may further lower the blood pressure.</p>
<p>Limited experience with dialysis indicates that it is not helpful.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_43f49ca4-7c8b-430c-a7d9-a4fa756d2c8f"></a><a name="section-13"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Promethazine hydrochloride and phenylephrine hydrochloride syrup is contraindicated for children under 2 years of age (</span>see <span class="Bold">WARNING:</span></p>
<p><span class="Bold">  </span>and <span class="Bold"><a href="#LINK_762a2330-0c55-425b-a53f-f678378f89a6">Use In Pediatric Patients</a>).</span></p>
<p>The recommended doses are given in the following table:</p>
<p><span class="Bold">Adults And Children 12 Years And Over</span></p>
<p>1 teaspoonful (5 mL) every 4 to 6 hours, not to exceed 6 teaspoonsful (30 mL) in 24 hours.</p>
<p><span class="Bold">Children 6 To Under 12 Years Of Age</span></p>
<p>½ to 1 teaspoonful (2.5 to 5 mL) every 4 to 6 hours, not to exceed 6 teaspoonsful (30 mL) in 24 hours.</p>
<p><span class="Bold">Children 2 To Under 6 Years Of Age</span></p>
<p>¼ to ½ teaspoonful (1.25 to 2.5 mL) every 4 to 6 hours.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_a8b72a27-61ca-45e3-bebf-17a70dbf8e60"></a><a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">This preparation is a yellowish-orange syrup with odor of apricot peach. Each 5 mL (one teaspoonful) contains promethazine hydrochloride 6.25 mg, phenylephrine hydrochloride 5 mg, and alcohol 7 percent.</p>
<p>118cc bottle – NDC 68788-6763-1</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_b661aba6-d645-4711-aa88-1971883ed5ec"></a><a name="section-14.1"></a><p></p>
<p class="First">Keep tightly closed. Protect from light.</p>
<p>Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container with a child-resistant closure as defined in the USP.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5fa73e4f-c494-4c3d-a4c2-45d31396a364"></a><a name="section-15"></a><p></p>
<p class="First">Manufactured for:<br><span class="Bold">QUALITEST PHARMACEUTICALS</span><br>Huntsville, AL 35811</p>
<p>8181658<br>R5/08-R1</p>
<p><span class="Bold">Relabeled by Preferred Pharmaceuticals, Inc. </span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_bbfd4c19-4434-4b21-8fbb-24bd45d08dac"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id1593742772"></a><img alt="Prometh VC Syrup" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1ed2a01c-6521-451e-819f-7464562314a3&amp;name=1ed2a01c-6521-451e-819f-7464562314a3-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROMETHAZINE VC 		
					</strong><br><span class="contentTableReg">promethazinehydrochloride and phenylephrine hydrochloride syrup</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68788-6763(NDC:0603-1587)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROMETHAZINE HYDROCHLORIDE</strong> (PROMETHAZINE) </td>
<td class="formItem">PROMETHAZINE HYDROCHLORIDE</td>
<td class="formItem">6.25 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PHENYLEPHRINE HYDROCHLORIDE</strong> (PHENYLEPHRINE) </td>
<td class="formItem">PHENYLEPHRINE HYDROCHLORIDE</td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASCORBIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MENTHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (Yellowish-Orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">APRICOT (Apricot-Peach) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68788-6763-1</td>
<td class="formItem">118 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040654</td>
<td class="formItem">07/25/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Preferred Pharmaceuticals, Inc.
							(791119022)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Preferred Pharmaceuticals, Inc. (791119022)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Preferred Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">791119022</td>
<td class="formItem">RELABEL(68788-6763)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f5e9c751-17e2-40d1-83c6-263a1bee42f1</div>
<div>Set id: 1ed2a01c-6521-451e-819f-7464562314a3</div>
<div>Version: 2</div>
<div>Effective Time: 20150116</div>
</div>
</div> <div class="DistributorName">Preferred Pharmaceuticals, Inc.</div></p>
</body></html>
